Efficacy Assessment of Gluten Free Cupcakes
- Conditions
- Celiac Disease in Children
- Registration Number
- NCT06359613
- Lead Sponsor
- University of Veterinary and Animal Sciences, Lahore - Pakistan
- Brief Summary
Randomized controlled trial will be conducted after getting informed consent form from each study participant meeting inclusion criteria (n=70, 35 control group +35 intervention group, 3-8years of age). After consumer acceptance against various attributes of aglutenic cupcake, the product will be provided in polyethylene bags containing 28 cupcakes (35gm by weight/cupcake, 2 cupcakes for each day) providing approximately 20% daily value (DV) of energy. Cupcakes of equal weight and size made with rice flour (mostly used recipe) will be provided to the control group. Further product will be provided on follow-up visits. The compliance to a gluten free diet GFD and supplemented product will be confirmed by a Food Frequency Questionnaire (FFQ).
- Detailed Description
Raw Material/ Preparation of flour blends for aglutenic (gluten free) cupcakes:
Sorghum, chickpea, Flaxseed and Almond rich in healthy nutrients will be purchased from the local market. All these ingredients was ground into fine powder using uncontaminated grinder. Different flour blends was prepared by substituting whole wheat flour with Sorghum, Chickpea, Flaxseed and Almond flour at different replacement levels.
The efficacy study protocol was approved by the Bioethics Committee for randomized controlled trial (RCT). Written informed consent was obtained by the parents of children or their legal guardian.
Target population: Celiac Disease/gluten sensitive patients (n= 70, 35 control + 35 intervention) was recruited according to European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria.
Inclusion criteria:
In accordance with the inclusion criteria, boys and girls suffering from celiac disease was recruited:
* Positive trans-glutaminase antibody (tTG) as currently recommended test is the serum Immunoglobulin A (IgA) tissue trans-glutaminase antibody (tTG). The test has a sensitivity and specificity of greater than 90%.
* Clinical response to gluten free diet
* In the age range of 3-8 years
Exclusion Criteria:
* Patients on any other designed diet
* Taking vitamins and mineral supplements
* Individuals presenting with any other intestinal inflammatory disease, malignant diseases, chronic infections, thyroid, renal or hepatic alterations
* Taking drugs known to effect lipid and /or carbohydrate metabolism will be excluded from the study.
Effect of interventional product on nutritional status of participants will be assessed through anthropometric measurements, gastrointestinal complaints and following hematological indices;
* Complete Blood Count (CBC) WBCs, RBCs, MCV, Hb. , Hct. , Platelets
* Total Protein
* Lipid Profile HDL, LDL, VLDL, Cholesterol
* SGPT, SGOT
* Serum Electrolytes (Na ,Ca, K)
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 75
- Positive tissue trans-glutaminase antibody (tTG)
- Clinical response to gluten free diet
- Vitamins and mineral supplements
- Intestinal inflammatory diseases
- Malignant diseases of intestines
- Chronic infections,
- Thyroid, renal or hepatic alterations
- Celiac patients with diabetes
- Taking drugs known to effect lipid and /or carbohydrate metabolism
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Total Protein 12 weeks Serum Total Protein g/dL
Mid upper Arm Circumference (MUAC) 12 weeks Mid-upper arm circumference (MUAC) in centimeters will be measured midpoint between the acromion process of the scapula and the tip of the elbow.
Serum Electrolytes 12 weeks Sodium mmol/L Calcium mg/dL Potassium mmol/L
Body Weight 12 weeks Body weight (in kilograms) will be measured using a weight machine with standardization done after every 20 readings.
Height of the patients 12 weeks Height (in centimeters) will be measured (without shoes) in the position, back and hips touching the wall by using wall mounted stedio-meter
Body Mass Index (BMI) 12 weeks BMI will be calculated by using standard formula as weight in kilograms divided by height in meter square kg/m2. World Health Organization (WHO) standard growth charts, designed separately for boys and girls will be used as a research tool to assess the nutritional status.
Complete Blood Count (CBC) 12 weeks White Blood Cells 10\^9/L Red Blood Cells million/mm3 Mean Corpuscular Volume 10\^6/µL Hemoglobin g/dL Hematocrit % Platelets 10\^9/L
Lipid Profile 12 weeks High Density Lipoproteins mg/dL Low Density Lipoproteins mg/dL Very Low-Density Lipoproteins mg/dL Serum Total Cholesterol mg/dL
Liver Enzymes 12 weeks serum glutamic-pyruvic transaminase SGPT- U/L, serum glutamic-oxaloacetic transaminase SGOT-U/L
- Secondary Outcome Measures
Name Time Method Gastrointestinal Symptoms 12 weeks Rate of diarrhea, constipation, Severity of abdominal pain, steatorrhea, flatulence and appetite will be monitored by using Gastrointestinal Rating Scale with addition of Steatorrhea.
Trial Locations
- Locations (1)
UVAS
🇵🇰Lahore, Punjab, Pakistan
UVAS🇵🇰Lahore, Punjab, Pakistan